http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011184423-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37caa7c14ee6a6f4a1ae73318957b0ba |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2010-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d8a02fa6b84151771599d275652a219 |
publicationDate | 2011-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2011184423-A |
titleOfInvention | Dipeptide derived from Okinawa mozuku, L-isoleucyl-L-tryptophan and angiogenesis inhibitor |
abstract | To provide a dipeptide derived from Okinawa mozuku, which extracts a protein from the extract of Okinawa mozuku, and further has angiogenesis inhibitory activity from this protein. A dry powder of Okinawa mozuku is extracted with a weak alkaline aqueous solution and then fractionated with ethanol to obtain a protein derived from Okinawa mozuku. The peptide derived from Okinawa Mozuku obtained by further cleaving into peptide chains and then isolated and purified by reverse phase HPLC is L-isoleucil-L-tryptophan, has angiogenesis inhibitory activity, and has anticancer effects. And extremely low toxicity. [Selection figure] None |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102495169-A |
priorityDate | 2010-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 418.